Alnylam Pharmaceuticals presented complete results from the company’s ILLUMINATE-B Phase III study in children under 6 years with primary hyperoxaluria type 1 (PH1), a rare disorder affecting the kidneys.
The European medicines watchdog recommended approving AstraZeneca’s treatments for a form of heart failure and a lung disorder, the British drugmaker said.
AstraZeneca’s Farxiga improved survival chances for patients suffering from kidney disease, underscoring the medicine’s role outside the drug’s established field of diabetes.
bluebird bio Inc. announced updated results from the clinical development program for the company’s investigational elivaldogene autotemcel (eli-cel, Lenti-D) gene therapy in patients with cerebral adrenoleukodystrophy (CALD), including long-term results from the Phase 2/3 Starbeam study and data from the Phase 3 ALD-104 study.
For all the digital and interactive tools that keep popping up, television remains the DTC marketer’s old reliable.
A panel of the European medicines regulator recommended approving Novo Nordisk’s new diabetes pill Rybelsus, further boosting prospects for the Danish drugmaker with the company’s first-of-a-kind, non-injectable treatment.
The software of life is how Moderna Inc. CEO Stephane Bancel describes messenger RNA (mRNA), which is at the core of the company’s drug development process.
AstraZeneca topped the first annual Pharmaceutical Invention Index, released by IDEA Pharma.
Pliant Therapeutics and Novartis reached a strategic collaboration and license deal to develop and commercialize integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis (NASH).
The U.S. Food and Drug Administration granted Fast Track designation for mRNA-3927, Moderna Inc.’s investigational messenger RNA therapeutic for propionic acidemia (PA).